Using Race in Clinical Research to Develop Tailored MedicationsIs the FDA Encouraging Discrimination or Eliminating Traditional Disparities in Health Care for African Americans?

2006 ◽  
Vol 27 (2) ◽  
pp. 225-241 ◽  
Author(s):  
Michael D. Ruel
Healthcare ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 100555
Author(s):  
Mark P. Sendak ◽  
Michael Gao ◽  
William Ratliff ◽  
Krista Whalen ◽  
Marshall Nichols ◽  
...  

2021 ◽  
pp. 174077452110015
Author(s):  
E Ray Dorsey ◽  
Karl Kieburtz

The proposed triple aim of health care—enhanced patient experience, improved population health, and reduced per capita costs—can be applied to clinical research. A triple aim for clinical research would (1) improve the individual research participant’s experience; (2) promote the health of populations; and (3) reduce per capita costs of clinical research. Such an approach is possible by designing trials around the needs of participants rather than sites, embracing digital measures of health, and advancing decentralized studies. Recent studies, including those evaluating therapies for COVID-19, have demonstrated the value of such an approach. Accelerating the adoption of these methods can help fulfill this new triple aim of clinical research.


1998 ◽  
pp. 203-226 ◽  
Author(s):  
Patricia A. Marshall ◽  
Barbara A. Koenig ◽  
Paul Grifhorst ◽  
Mirjam van Ewijk

2017 ◽  
Vol 68 (3) ◽  
pp. 264-270 ◽  
Author(s):  
Patrick W. Corrigan ◽  
Dana J. Kraus ◽  
Susan A. Pickett ◽  
Annie Schmidt ◽  
Ed Stellon ◽  
...  

2017 ◽  
Vol 5 (1) ◽  
pp. 111-116 ◽  
Author(s):  
Diane Orr Chlebowy ◽  
Mary-Beth Coty ◽  
Liyan Fu ◽  
Vicki Hines-Martin

Sign in / Sign up

Export Citation Format

Share Document